Methylenedioxybenzylamphetamine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 12:50, 6 October 2015 (Updating {{chembox}} (changes to verified fields - updated 'UNII_Ref', 'Verifiedfields') per Chem/Drugbox validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Methylenedioxybenzylamphetamine
Names
IUPAC name
1-(1,3-benzodioxol-5-yl)-N-benzylpropan-2-amine
Identifiers
3D model (JSmol)
UNII
  • C1=C3C(=CC=C1CC(C)NCC2=CC=CC=C2)OCO3
Properties
C17H19NO2
Molar mass 269.343 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

MDBZ, or 3,4-methylenedioxy-N-benzylamphetamine, is a lesser-known psychedelic drug. It is the N-benzyl derivative of MDA. MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. MDBZ produces few to no effects. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.

In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to 3,4-methylenedioxy-N-benzylamphetamine.[1]

See also

References

  1. ^ "House of Commons Hansard Written Answers for 23 July 1996 (pt 10)".

External links

Template:PiHKAL